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Abstract
Rationale: Tuberculosis treatment lasts for six months or more. Treatment adherence is critical; 
regimen length, among other factors, makes this challenging. Globally, analyses mapping 
common types of non-adherence are lacking. For example, is there a greater challenge from 
early treatment cessation (discontinuation) or intermittent missed doses (suboptimal dosing 
implementation)? This is essential knowledge for the development of effective interventions, 
more ‘forgiving’ regimens, and to direct National Tuberculosis Programs.
Objective: Granularly describe how patients take their tuberculosis medication and the 
temporal factors associated with missed doses.
Methods: Pulmonary tuberculosis patients enrolled in the control arm of a pragmatic cluster-
randomized trial in China of electronic reminders to improve treatment adherence were 
included. Treatment was the standard six-month course (180 days), dosed every other day (90 
doses). Medication monitor boxes recorded adherence (box opening) without prompting 
reminders. Patterns of adherence were visualized and described. Mixed-effects logistic 
regression models examined the temporal factors associated with per-dose suboptimal dosing 
implementation, adjusting for clustering by participant. Cox regression models examined the 
association between early suboptimal dosing implementation and permanent discontinuation.
Results: Across 780 patients, 16,794 of 70,200 doses were missed (23.9%), 9,487 from 
suboptimal dosing implementation (56.5%). By 60 days, 5.1% of participants had discontinued, 
14.4% by 120 days. Most participants (95.9%) missed at least one dose. The majority of gaps 
were of a single dose (71.4%), although 22.6% of participants had at least one gap of two 
weeks’ or more. In adjusted models, the initiation-continuation phase transition (odds ratio 
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3.07 [95% confidence interval 2.68-3.51]) and national holidays (1.52 [1.39-1.65]) were 
associated with increasing odds of suboptimal dosing implementation. Early-stage suboptimal 
dosing implementation was associated with increased discontinuation rates.  
Conclusions: Digital tools provide an unprecedented step-change in describing and addressing 
non-adherence. In our setting, non-adherence was common; patients displayed a complex 
range of patterns. Dividing non-adherence into suboptimal dosing implementation and 
discontinuation, both were found to increase over time. Discontinuation was associated with 
early suboptimal dosing implementation. These apparent causal associations between temporal 
factors and non-adherence present opportunities for targeted interventions.
Clinical Trial Registration: ISRCTN46846388
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In 2017, 6.4 million incident tuberculosis (TB) cases were reported globally and an estimated 
3.6 million went undiagnosed or were not notified.(1) Finding and treating these missing 
patients is a key target of the World Health Organization (WHO); this requires substantial 
international investment. It is critically important to protect this investment by providing 
effective treatment to every diagnosed patient.
The standard treatment for drug sensitive TB lasts for six months. Numerous studies 
have documented that patients struggle to adhere to the full course of therapy. An estimated 4-
35% demonstrate poor adherence.(2-11) Although various definitions have been used, poor 
adherence is associated with a reduced likelihood of sputum conversion,(3) greater risk of an 
unsuccessful treatment outcome,(4, 8, 12-15) and the development of drug resistance.(16-19) 
Non-adherence to TB treatment is associated with various factors; those that are patient-
related, derived from the healthcare provider-patient relationship, the regimen itself, and the 
healthcare system.(20)
In trials and observational studies, overly simplistic and non-evidence-based 80-90% 
adherence thresholds have traditionally been used to signify adequate adherence.(12, 21-23) 
Recently, however, the importance of highly accurate means of measuring adherence within 
clinical trials has been acknowledged by WHO as a key part of trial design.(24) Realistically, two 
core domains need to be considered when mapping adherence- persistence (time between first 
and last doses; capturing initiation and discontinuation) and dosing implementation (taking 
doses not as recommended e.g. skipping weekends).(25) These components constitute 
‘therapeutic coverage’, the proportion of time patients are exposed to efficacious drug 
concentrations.(26) Detailed mapping of adherence patterns has been missing from the TB 
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literature to date.
Knowledge of how exactly TB patients take their medications and predictors of when 
non-adherence is most likely to occur is critical for the directed design of interventions to 
improve adherence, the development of regimens that are more ‘forgiving’ of non-adherence, 
and to help clinicians know when to intervene with non-adherent patients. Currently, the 
relative burden of suboptimal dosing implementation and discontinuation is unknown globally; 
interventions to address these two components of non-adherence may look quite different. 
This is a critical knowledge gap when it comes to reducing the burden of non-adherence, which 
is impeding the most cost-effective implementation of the WHO guidelines on digital adherence 
technologies for TB treatment.(27)
Utilizing data collected from a trial of electronic reminders to improve medication 
adherence in China, we aimed to granularly describe how TB patients take their treatment and 
if temporal factors were causally associated with missed doses in order to inform control 
efforts. Components of this study have been previously reported through a conference 
abstract.(28)
Methods
Parent Study and Study Population for Analysis
The parent study- a pragmatic cluster randomized trial of electronic reminders to improve 
treatment adherence among pulmonary TB patients in People’s Republic of China- from which 
these data has been derived has been described before (Online supplement Additional 
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Methods).(29) Participants were enrolled into the study between 1st June 2011 and 7th March 
2012. Only participants in the control arm of the trial were included in this cohort study in order 
to capture usual patterns of treatment adherence in the absence of an intervention (Online 
supplement Additional Methods).
Measuring and Defining Adherence to Treatment
Adherence to each dose of treatment was documented by a medication monitor box (Online 
supplement Additional Methods). The box captured every date and time on which it was 
opened; box opening did not necessarily mean that drugs were taken. Medication was dosed 
every other day (as per the National TB Program [NTP] standard at the time), for 90 doses over 
a 180-day period. If the box was opened at least once within each two-day dosing window this 
was recorded as adherence. The standard six-month regimen for drug sensitive TB was used 
(two months of isoniazid, rifampicin, ethambutol, pyrazinamide, followed by four months of 
isoniazid and rifampicin). Medication was not dosed in combination pills.
Non-adherence data from the monitor was coded, and categorized as a dose missed due 
to suboptimal dosing implementation versus a dose missed due to permanent discontinuation, 
using accepted terminology as per Vrijens et al.(25) Discontinuation was defined as ceasing to 
adhere to treatment and not re-commencing both a) at any point during the 180-day period 
and b) after this period but before the end of the trial. Discontinuation is different from the 
programmatically defined term ‘lost to follow-up’ (previously known as ‘default’), when either a 
patient’s treatment is interrupted for consecutive two months or more, or a patient does not 
start treatment. Suboptimal dosing implementation refers to all doses missed during the 180-
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day period, aside from those due to discontinuation. The term ‘suboptimal’ is not intended to 
imply a judgement as to the appropriate level of adherence/type of adherence pattern required 
to achieve a positive treatment outcome, but rather reflects an implementation level below 
100% of doses taken.
Temporal Exposures and Potential Confounders
The following temporal measures were calculated from the medication monitor data: 1) day of 
the week, 2) treatment month, 3) whether the dose fell on a Chinese national holiday, 4) 
whether the patient was in the initiation or continuation phase of treatment (see Online 
supplement Additional Methods).
Additionally, data were available for a series of potential confounders, all of which were 
self-reported at entry into the study. These included age, sex, marital status, educational level, 
occupation, household income, type of medical insurance, registration status, and distance 
from home to TB clinic. The county/district in which the participant lived was grouped into 
whether it was broadly rural or urban.
Statistical Methods
Descriptive analyses. Analyses were undertaken in Stata 15 and graphs plotted in Microsoft 
Excel.
Adherence to treatment was described using the following summary measures: the 
overall percentage of doses taken, average duration that a patient was on treatment before 
ceasing completely, percentage of participants achieving an 80% adherence threshold, and 
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percentage achieving a 90% threshold. In order to account for clustering, for each measure the 
mean was calculated per county/district and then the geometric mean taken across the 
county/district values.
Adherence over time, grouped by different percentage intervals, was graphically 
visualized using lasagna plots, in which white indicates non-adherence.(30) 
Line graphs were used to visualize non-adherence due to suboptimal dosing 
implementation versus permanent discontinuation from treatment for all participants in the 
study and by adherence levels in the initiation phase.(31) After plotting these graphs, we 
decided to separate suboptimal dosing implementation and discontinuation in the remaining 
analyses.
The length and number of gaps in treatment due to suboptimal dosing implementation 
were described using scatter plots.
Associations between temporal factors and suboptimal dosing implementation. We 
used mixed-effects logistic regression to examine the factors associated with non-adherence 
due to suboptimal dosing implementation, treating each dose as an observation and adjusting 
for clustering by individual. We focused on temporal factors, including weekends, national 
holidays, and the initiation-continuation phase transition (Model 1) or treatment months 
(Model 2). Our methodology- including details of model selection through the use of directed 
acyclical graphs, determination of a priori confounders, and assessment of potential effect 
modification- is detailed elsewhere (Online supplement Additional Methods). The impact of 
using different confounder sets on our findings was explored through Models 1A-F (Online 
supplement Additional Methods). Both approaches sought to address all confounding using 
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different confounder sets to support the drawing of causal conclusions from observational 
data.(32)
The potential presence of an interaction between the three temporal factors weekends, 
national holidays, and the initiation-continuation phase transition and a) county/district or b) 
distance from home to TB clinic were also explored using likelihood ratio tests (LRTs) (Models 
1G-H).
Associations between early suboptimal dosing implementation and time to 
discontinuation. Cox proportional hazards regression was used to assess whether early 
suboptimal dosing implementation, either in the initiation phase (Model 3) or month 1 (Model 
4), was associated with time to discontinuation. Individuals who had discontinued in the 
initiation phase and month 1 were excluded, respectively, in order to preserve the temporality 
of the association. Further details on adjustment for confounding, etc., are presented in Online 
supplement Additional Methods. We report sensitivity analyses on the impact of confounding 
by county/district (Models 3F, 4F) and excluding individuals who discontinued during the last 
three doses of treatment (Models 3G, 4G). The potential presence of an interaction between 
early suboptimal dosing and a) county/district or b) distance from home to the TB clinic were 
also explored using LRTs.
Ethical Approval
The trial was approved by the ethics committees of the Chinese Center for Disease Control and 
Prevention (201008) and the London School of Hygiene & Tropical Medicine (5704). All 
participants provided written consent prior to inclusion in the trial.
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Results
Characteristics of the Study Population
Of the 1,104 individuals randomized to the control arm of the trial, 209 (18.9%) had technical 
issues with the medication monitor due to power outage problems, as indicated by the box 
resetting the date to a baseline value (Online supplement Figure E1). A further 10.4% of 
patients (115) were excluded, as events such as hospitalization for more than three days 
removed the potential for treatment to be monitored for the entire period. Thus 780 (70.7%) 
patient’s data were available for analysis. A comparison of the included and excluded patients 
revealed similarity in terms of baseline characteristics, except for county/district and distance 
from home to the TB clinic (Table E1).
The baseline characteristics of participants are presented in Table 1. Individuals were 
generally male (535, 68.6%). More than half were under the age of 50 (525, 67.3%). Farming 
was the largest occupation (384, 49.2%), with 516 (66.2%) individuals living in counties/districts 
deemed rural and 500 (64.1%) insured through rural co-operatives.
Summary Measures of Overall Adherence
Across all 780 study participants, 70,200 doses were scheduled during the 180-day period; 
16,794 of these were missed (23.9%). The geometric mean number of doses taken was 68/90 
(75.6%). The geometric mean duration on treatment was 80 doses (i.e. 160 days) before 
discontinuation. 
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Overall Adherence over Time
Lasagna plots of adherence over time demonstrated the distribution of participants in 20% 
adherence intervals, with 473/780 (60.6%) in the highest category of ≥80-100% adherent 
(Figure 1). A clear ‘staggered’ pattern was observed in the lowest categories that corresponded 
to drop-offs in adherence with each passing month (15 doses, 30 days). Although there was a 
reduction in adherence over time, erratic non-adherence (suboptimal dosing implementation) 
was observed throughout the treatment period.
The relative importance of non-adherence due to the permanent discontinuation of 
treatment versus suboptimal dosing implementation is shown in Figure 2a. Of the 16,794 
missed doses, 9,487 were due to suboptimal dosing implementation (56.5%) and the remainder 
discontinuation. The impact of discontinuation was demonstrably stronger over time. By the 
end of month 2 5.1% of individuals had discontinued treatment; this figure was 14.4% by the 
end of month 4 and continued to increase during the last two months, until it reached 36.3% at 
the end of the 180-day period. The latter figure reflects the fact that discontinuation captures 
treatment cessation without recommencement at any time point, including cessation at the last 
(90th) dose.
When the 121 participants with <80% adherence in the initiation phase were examined 
separately, they demonstrated sharp and sustained reductions in adherence due to both 
discontinuation and suboptimal dosing implementation (Figure 2c).
Gaps in Adherence (Suboptimal Dosing Implementation)
Suboptimal dosing implementation was demonstrated by 748/780 (95.9%) participants i.e. they 
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displayed at least one gap in their treatment of one dose or more that was not due to 
discontinuation. Overall, a total of 4,677 gaps were recorded, of which 71.4% (3,337/4,677) 
were for one dose only. The population median of the median gap length per participant was 
one and the interquartile range (IQR) 1-1 (Figure 3a). When the maximum gap length per 
participant was examined, the median across the population was two doses (IQR 1-6; Figure 
3b). Of the 780 individuals, 368 (47.2%) had at least one gap of three doses (roughly a week) or 
more and 176 (22.6%) of seven doses (a fortnight) or more.
Associations between Suboptimal Dosing Implementation and Temporal Factors
Our analysis of suboptimal dosing implementation and temporal factors was composed of 780 
patients and 62,893 dose observations (Table 1). In unadjusted analyses, a strong association 
was seen between the initiation-continuation phase transition and suboptimal dosing 
implementation. The continuation phase was associated with triple the odds of suboptimal 
dosing implementation (odds ratios [OR] 3.09 [95% confidence interval {CI} 2.70-3.54]). This 
mirrors the month-by-month findings, where suboptimal dosing implementation increased 
from 6.8% of doses in treatment month 1 to 19.7% in month 6. Sunday was associated with 
greater suboptimal dosing implementation than the other days of the week (p<0.001). 
Compared to weekdays, weekends were associated with a small increase in the odds of 
suboptimal dosing implementation (1.13 [1.07-1.19]). National holidays were associated with a 
larger increase in odds (1.62 [1.49-1.75]; 14.6% to 20.5%).
In an adjusted model controlling for age as a linear variable, sex and urban/rural setting, 
and with a random effect on the initiation-continuation variable ([LRT p-value <0.001), all three 
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temporal variables were associated with greater odds of suboptimal dosing implementation 
(weekends: 1.14 [1.08-1.20]), national holiday: 1.52 [1.39-1.65]), initiation-continuation 
transition 3.07 [2.68-3.51] (Model 1). There was no evidence for interactions between the 
initiation-continuation transition and national holidays (LRT p-value 0.97) or weekends (LRT p-
value 0.07). These findings were robust to adjustment for different combinations of 
confounders (Table E2; Models 1A-F).
Tests for interaction were performed between the three temporal factors and 
county/district or distance. For distance, the LRT p-values for the initiation-continuation phase 
transition, holidays and weekends were 0.52, 0.97 and 0.91, respectively. For county/district, 
the LRT p-values for the initiation-continuation phase transition, holidays and weekends were 
0.01, <0.001, 0.79, respectively. We thus undertook stratified analyses by county/district of the 
relationship between suboptimal implementation and a) the initiation-continuation phase 
transition (Table E3, Model 1G) or b) holidays (Table E4, Model 1H). Although the magnitude of 
the relationship between these two temporal factors and suboptimal implementation altered 
by county, the direction of effect was the same in all instances, barring one instance where the 
CI crossed the null (Baiquan, Model 1H; 0.94 [0.75-1.18]).
Given the striking initiation-continuation phase effect found in these models, but also 
the more gradual pattern of reducing adherence demonstrated in Figure 1, the association 
between treatment month and suboptimal dosing implementation was assessed. A random 
effect was included on the treatment month (LRT p-value <0.001), which was treated as a 
categorical variable. An interaction was documented between treatment month and national 
holidays (LRT p-value 0.01), but the statistical evidence was less certain for an interaction 
Page 14 of 49 ANNALSATS Articles in Press. Published on 20-December-2019 as 10.1513/AnnalsATS.201905-394OC 
 Copyright © 2019 by the American Thoracic Society 
between treatment month and weekends (LRT p-value 0.06).
Within a model containing the treatment month-national holiday interaction (Model 2), 
the association between weekends and the odds of non-adherence due to suboptimal dosing 
implementation changed little from Model 1 (1.14 [1.08-1.20]). From month-to-month, the 
likelihood of suboptimal dosing implementation approximately increased and was particularly 
pronounced for doses that fell on national holidays (Table 2). A dose falling on a national 
holiday was positively associated with suboptimal dosing implementation, with the largest 
increase in odds in the last month of treatment, but no clear trend month-to-month (Table 2). 
Associations between Time to Discontinuation and Early Suboptimal Dosing Implementation
Among the individuals included in the study, 109 were found to stop treatment without 
recommencing within the 90-dose period, but to later recommence before the end of the trial. 
The latest dose taken was at 254 days. These individuals were not classified as discontinuing. 
Patients who discontinued during the relevant implementation period were excluded in order 
to preserve temporality within any associations. Thus, 740 patients contributed to an analysis 
of discontinuation and suboptimal dosing implementation in the initiation phase and 775 when 
suboptimal dosing implementation in month 1 was instead considered (Table 1).
In unadjusted analyses, increased suboptimal dosing implementation in the initiation 
phase and month 1 were associated within an increase in the likelihood of discontinuation 
(Table 1). These findings were robust in an adjusted analysis (Table 3). The impact of ≥80 to 
<90% versus ≥90% adherence was less certain for the initiation phase analysis (Model 3), but 
more suggestive of a dose-response association in the month 1 analysis (Model 4). Considering 
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different confounder sets, these models were robust to adjustment for a fixed effect for 
county/district rather than urban/rural (Table E5; Models 3F and 4F). When the 52 individuals 
who discontinued from dose 87 onwards were excluded, our effect estimates increased for 
both the initiation phase and month 1 analyses (Table E5; Models 3G and 4G). Tests for 
interaction between early suboptimal dosing implementation and county/district revealed no 
evidence for an effect (LRT p-value 0.19).
Discussion
Our analysis of adherence- both suboptimal dosing implementation and discontinuation- 
among pulmonary TB patients in China provides the first detailed description of how doses are 
missed over the six-month treatment period. We found that participants took 76% of their 
doses; 61% took 80% or more. The use of simple percentage thresholds, however, masks 
important variation in the patterns of missed doses over time. 
Of all missed doses, 43% were due to discontinuation. A steady increase in non-
adherence due to both suboptimal dosing implementation and discontinuation over time was 
observed. At two months, 5.1% of participants had discontinued their medication, 14.4% at four 
months, and 36.3% by the end of the 180-day period. During the intensive phase of treatment 
(the first two months), suboptimal dosing implementation accounted for the majority of non-
adherence. Of the 19% of patients who were non-adherent at the end of the intensive phase, 
discontinuation accounted for 27% of the non-adherence and suboptimal dosing 
implementation the remainder. During the continuation phase (months 3 to 6), the odds of 
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suboptimal dosing implementation were three times higher than during the intensive phase, 
but the percentage of patients with suboptimal dosing implementation remained stable at 17-
20%. However, the percentage of those who discontinued treatment continued to accumulate, 
and by the fifth month, discontinuation accounted for 52% of all non-adherence.
We identified an important association between suboptimal dosing implementation 
early in the course of treatment and subsequent discontinuation. Suboptimal dosing 
implementation in the first month or overall initiation phase (months 1 and 2) was associated 
with higher discontinuation rates. Across participants, 96% demonstrated suboptimal dosing 
implementation; around three quarters of gaps were for one dose only. Nevertheless, 47% of 
individuals had potentially clinically important gaps of three consecutive doses or more and 
23% of seven consecutive doses (a fortnight) or more. The odds of suboptimal dosing 
implementation were higher on national holidays (OR 1.52).
The findings of this study provide several insights into how drug-sensitive TB treatment 
can be improved. Firstly, NTPs should take seriously the problem of non-adherence to 
treatment, which is under-recognized. In this study, a high percentage of patients had gaps of a 
week or more in their treatment due to suboptimal dosing implementation. If these gaps are 
not recognized and treatment is not adjusted accordingly, then long-term, relapse-free, cure of 
these patients may be compromised. NTPs should place a much higher priority on improving 
adherence during treatment and not simply focus on ensuring completion.
Second, this study identified the importance of early adherence. Adherence worsened 
over the course of treatment, especially after the shift into the continuation phase. We also 
found an association between discontinuation and early suboptimal dosing implementation. 
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Thus improving adherence early in the course of treatment may be important to prevent later 
non-adherence.
Third, this study highlights the importance of granular adherence data on individual 
patients. Early identification of individuals with poor adherence or who discontinue would 
improve the likelihood of success of adherence-promoting interventions. Identification of such 
individuals could result in the initiation of differentiated care, which would include more 
tailored adherence support for these patients. The design of such behavioral interventions 
should take into account data on the types of non-adherence displayed by the target 
population and their causes. For example, plans to support medication adherence may need to 
be proactively generated with patients before holiday periods, where travel to different 
locations may generate greater concern about stigma and result in missed doses. Adherence 
should also be monitored after such interventions are deployed, to check for improvement. 
Digital technologies to record adherence- e.g. by using pill bottle opening as a surrogate for 
medication intake- have been available for many years and are starting to be rolled out globally, 
despite operational barriers such as cost.(33) Such technologies, however, provide an 
opportunity to monitor TB treatment adherence for individual patients on a large scale.(33) 
Fourth, these results lend support to the development of shorter treatment regimens, 
which may avoid the adherence drop-off later in treatment that is currently observed. Such 
regimens have not yet demonstrated non-inferiority (34-36) and will likely, however, increase 
the importance of each individual dose in ensuring cure. Retrieving patients who default from 
treatment is a large financial burden on NTPs; this could also be reduced with shorter regimens 
that result in less discontinuation. We also highlight the value of examining  discontinuation of 
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treatment, rather than programmatically defined loss to follow-up/default, in terms of 
capturing effective drug exposure. 
Overall, studies prior to ours have provided the initial basis of a link between different 
adherence patterns and treatment outcomes in drug sensitive disease.(2-9, 11) For example, 
missing 8-16% of doses has been associated with 25 times the odds of remaining sputum 
positive,(3) adhering below a 90% threshold with 5.9 times the rate of an unfavorable 
outcome,(15) adhering below a 75% threshold with 3.2 times the odds of recurrence,(14) 
adhering below a 90% threshold with 3.4 times the odds of mortality,(4) and ‘irregular’ drug 
taking such that treatment had to be extended 2.5 times increased odds of relapse.(8) 
Conversely, a regimen simulating <67% adherence had no impact on recurrence.(37) 
Additionally, previous studies have documented a 17% additional hazard per month of acquired 
drug resistance if adherence is <80%,(19) or 19.7 times the odds of with half month gaps, non-
engagement or <80% adherence.(16) This association is not simple; particularly poor adherence 
may exert little selective pressure.(17) In drug resistant disease, there is a smaller but less 
contradictory evidence base in terms of the implications of non-adherence: long interruptions 
and <80-90% adherence have been associated with poorer outcomes.(17, 19, 38, 39) What 
these studies lack- which potentially explains their conflicting findings- is a granular exploration 
of how non-adherence influences treatment outcomes using reliable sources of adherence 
data.(23) Our study indicates that poor adherence is complicated and heterogeneous; future 
studies will require granular dose-by-dose data in order to properly assess the non-adherence-
outcomes relationship. Future studies should collect detailed adherence data- moving away 
from monthly self-reported information and chart reviews- to ascertain how they correlate to 
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therapeutic coverage, pharmacokinetics (TB drugs with a short half-life are predicted to be less 
forgiving), sputum conversion rates, treatment outcomes,(40) relapse (the gold standard 
outcome measure), and the development of drug resistance.
This is the most detailed analysis to date of treatment adherence in TB, which makes 
use of exceptionally granular adherence data. It does, however, have its limitations. Whether 
drug intake was supported (e.g. observed by a family member) or self-administered was not 
documented, potentially leaving residual confounding. Opening the medication monitor box 
does not necessarily mean that drugs were taken, although a validation study has indicated 
high correlation with urine rifampicin levels.(41) Given that each dose could have been taken 
during a two-day period, non-differential misclassification of the temporal exposure variables 
may have occurred, biasing effect estimates towards the null. As fixed dose combination pills 
were not used, it is possible that non-adherence was underestimated per drug, as individuals 
may have chosen not to take all their pills per dose. The exclusion of participants for whom a 
whole dosing history was not available may have resulted in selection bias, as excluded 
participants differed from included participants in terms of the county/district in which they 
lived and their distance from home to their local TB clinic. On the basis of tests for interaction, 
it seems unlikely, however, than temporal factors (the focus of our analysis) are systematically 
differently associated with adherence across different levels of these variables. Data were 
missing on participant’s personal holidays, which could be biasing the effect size towards the 
null. Furthermore, part of the national holiday effect could represent individuals not 
transporting their monitor boxes with them when they travel, but nevertheless taking their 
medication. Socio-behavioral data on factors associated with non-adherence, such as stigma, 
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were not collected, potentially resulting in residual confounding. Finally, participants may have 
been aware that they would be less likely to have taken their drugs at weekends and thus 
switched their doses from weekends to weekdays to avoid non-adherence. This is a function of 
the every-other-day dosing of the regimen and would result an over-emphasized effect size.
Four key factors in our study affect generalizability: this was a 1) single country dataset 
of 2) pulmonary TB patients 3) enrolled in a trial who 4) took their drugs every other day. Being 
enrolled in a trial is thought to boost adherence and the individuals who consent to participate 
are often more likely to be adherent; adherence data are therefore also needed from 
observational studies globally.(42-44) We thus recommend the need for future studies using 
granular adherence data from observational studies undertaken in other nations.
Conclusions
In conclusion, we demonstrate how non-adherence to TB treatment is a complex issue that 
needs to be taken seriously. Adherence worsens over the course of treatment, but early-stage 
interventions (when suboptimal dosing implementation is first detected) may prevent later 
discontinuation. For such interventions to be accurately targeted to the patients most in need, 
individual-level adherence data is required on a large scale. Shorter TB treatment regimens may 
reduce the impact of worsening adherence over the treatment course.
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Figure Legends:
Figure 1. Lasagna plot of adherence. Each patient of the 780 participants in the control arm of 
the original trial is a row in the graph; white indicates a dose that has not been taken. 
Adherence calculated as a percentage of the 90 doses taken over the 180-day period and then 
grouped into 20% adherence intervals. Rows are colored by adherence group. Numbers in 
brackets indicate the number of individuals within each 20% adherence interval.
Figure 2. Relative contribution of discontinuation and suboptimal dosing implementation to 
non-adherence over time. Non-adherence due to discontinuation (ceasing treatment and not 
re-commencing; dark grey) versus suboptimal dosing implementation (sporadic missed doses; 
light grey) over time in a) the 780 control arm patients from the original trial, b) the 659 
patients would displayed ≥80% adherence during the initiation phase, c) the 121 patients who 
displayed <80% adherence in the initiation phase. Discontinuation is ceasing treatment at any 
stage, including only for the 90th dose. If, after the 90th dose, another was taken before the end 
of the trial, the patient is not recorded as having discontinued. Discontinuation is not the same 
as programmatically defined loss to follow-up/default. Graph style adapted from the work of 
Blaschke et al.[28] 
Figure 3. Gaps in adherence. Gaps during the 90-dose medication period among the 748 
participants who displayed suboptimal dosing implementation. Number of gaps per participant 
of any length plotted against a) the median gap length per participant, b) the maximum gap 
length per participant.
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Table 1. Baseline characteristics. Unadjusted analyses of factors associated with non-adherence due to suboptimal dosing implementation or 
discontinuation
Overall Analysis of suboptimal dosing implementation Analysis of discontinuation
 
 
Exposure variables Participants Col. % Doses Col. % Doses missed Row %
Unadjusted OR 
(95% CI)
Person 
time 
(doses)
Participants 
who 
discontinued
Unadjusted HR 
(95% CI)
Overall 780 100.0 62893 100.0 9487 15.1 - 62396 235 -
Sex    
Female 245 31.4 19804 31.5 2683 13.5 baseline 19649 161 baseline
Male 535 68.6 43089 68.5 6804 15.8 1.20 (0.99-1.45) 42747 74 1.00 (0.76-1.32)
Age categorized (years)      
<30 230 29.5 18305 29.1 2837 15.5 baseline 18157 69 baseline
30-39 128 16.4 10099 16.1 1315 13.0 1.01 (0.95-1.08) 10021 44 0.95 (0.87-1.04)
40-49 167 21.4 13518 21.5 2077 15.4  13422 56
50-59 136 17.4 11117 17.7 1712 15.4  11023 35
60+ 119 15.3 9854 15.7 1546 15.7  9773 31
Occupation      
Students 32 4.1 2529 4.0 428 16.9 1.01 (0.64-1.58) 2512 13 1.34 (0.76-2.37)
Worker 74 9.5 6102 9.7 722 11.8 0.61 (0.45-0.84) 6048 17 0.69 (0.42-1.15)
Migrant Worker 74 9.5 6167 9.8 815 13.2 0.76 (0.55-1.03) 6115 17 0.68 (0.41-1.13)
Farmer 384 49.2 30763 48.9 5347 17.4 baseline 30523 122 baseline
Unemployed/ Houseworker 63 8.1 5207 8.3 624 12.0 0.60 (0.43-0.84) 5165 17 0.81 (0.49-1.35)
Other 153 19.6 12125 19.3 1551 12.8 0.68 (0.53-0.86) 12033 49 1.02 (0.73-1.42)
Educational level      
Illiterate 60 7.7 4595 7.3 858 18.7 1.38 (0.92-2.07) 4557 20 1.43 (0.79-2.59)
Lower middle school 494 63.3 39999 63.6 6254 15.6 1.03 (0.78-1.35) 39692 154 1.25 (0.82-1.93)
Upper middle school 130 16.7 10571 16.8 1216 11.5 0.73 (0.52-1.02) 10484 37 1.13 (0.68-1.89)
University or more 96 12.3 7728 12.3 1159 15.0 baseline 7663 24 baseline
Total household income in last 
calendar year (RMB)      
≥20,000 446 57.2 36044 57.3 4994 13.9 baseline 35754 131 baseline
<20,000 334 42.8 26849 42.7 4493 16.7 1.31 (1.10-1.57) 26642 104 1.07 (0.83-1.38)
Medical insurance      
Rural co-op 500 64.1 40583 64.5 6604 16.3 1.23 (0.96-1.57) 40261 146 0.65 (0.48-0.89)
Urban workers 92 11.8 7843 12.5 946 12.1 0.86 (0.61-1.20) 7773 18 0.40 (0.24-0.69)
No insurance 132 16.9 9855 15.7 1350 13.7 baseline 9786 53 baseline
Other 56 7.2 4612 7.3 587 12.7 0.95 (0.64-1.41) 4576 18 0.71 (0.42-1.21)
Marital status      
1st marriage 551 70.6 45024 71.6 6707 14.9 baseline 44665 161 baseline
Unmarried 184 23.6 14421 22.9 2194 15.2 1.02 (0.82-1.26) 14305 57 1.11 (0.82-1.50)
Other 45 5.8 3448 5.5 586 17.0 1.15 (0.78-1.69) 3426 17 1.43 (0.87-2.35)
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Table 1. continued
Overall Analysis of suboptimal dosing implementation Analysis of discontinuation
 
 
Exposure variables Participants Col. % Doses Col. % Doses missed Row %
Unadjusted OR 
(95% CI)
Person 
time 
(doses)
Participants 
who 
discontinued
Unadjusted HR 
(95% CI)
County     
Baiquan 100 12.8 7629 12.1 1926 25.2 baseline 7581 46 baseline
Yilan 103 13.2 8683 13.8 1113 12.8 0.40 (0.29-0.56) 8605 15 0.26 (0.15-0.47)
Rugao 78 10.0 6366 10.1 844 13.3 0.39 (0.27-0.56) 6310 21 0.52 (0.31-0.87)
Jianhu 80 10.3 6938 11.0 1270 18.3 0.60 (0.42-0.86) 6878 13 0.29 (0.16-0.54)
Miluo 85 10.9 6961 11.1 1131 16.2 0.55 (0.39-0.78) 6905 24 0.55 (0.34-0.90)
Yueyanglou 81 10.4 5893 9.4 718 12.2 0.35 (0.24-0.50) 5856 42 1.21 (0.79-1.83)
Fengjie 70 9.0 5115 8.1 684 13.4 0.39 (0.27-0.56) 5088 40 1.34 (0.88-2.04)
Shapingba 79 10.1 6311 10.0 915 14.5 0.49 (0.34-0.70) 6258 18 0.45 (0.26-0.78)
Jiangbei 104 13.3 8997 14.3 886 9.8 0.29 (0.21-0.40) 8915 16 0.27 (0.16-0.49)
Rural/urban      
Rural 516 66.2 41692 66.3 6968 16.7 baseline 41367 159 baseline
Urban 264 33.8 21201 33.7 2519 11.9 0.67 (0.55-0.81) 21029 76 0.94 (0.71-1.23)
Residence      
Living in place of household 
registration 658 84.4 53187 84.6 8191 15.4 baseline 52768 198 baseline
Not living in place of 
household registration 122 15.6 9706 15.4 1296 13.4 0.80 (0.62-1.03) 9628 37 1.03 (0.72-1.46)
Distance from home to local TB 
clinic (km)      
<10 188 24.1 15984 25.4 2255 14.1 baseline 15847 37 baseline
10-19 191 24.5 15185 24.1 2199 14.5 1.05 (0.99-1.12) 15065 63 1.14 (1.04-1.24)
20-29 118 15.1 9596 15.3 1451 15.1  9524 40 -
30-39 149 19.1 11802 18.8 1782 15.1  11714 49 -
>=40 134 17.2 10326 16.4 1800 17.4  10246 46 -
Day     p<0.001  
Sunday - - 9009 14.3 1516 16.8 baseline - - -
Monday  - - 8997 14.3 1301 14.5 0.81 (0.74-0.89) - - -
Tuesday  - - 8939 14.2 1344 15.0 0.84 (0.77-0.92) - - -
Wednesday  - - 9004 14.3 1315 14.6 0.83 (0.76-0.91) - - -
Thursday  - - 8895 14.1 1426 16.0 0.93 (0.85-1.01) - - -
Friday  - - 9275 14.7 1251 13.5 0.74 (0.68-0.81) - - -
Saturday  - - 8774 14.0 1334 15.2 0.87 (0.80-0.95) - - -
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Table 1. continued
Overall Analysis of suboptimal dosing implementation Analysis of discontinuation
 
 
Exposure variables Participants Col. % Doses Col. % Doses missed Row %
Unadjusted OR 
(95% CI)
Person 
time 
(doses)
Participants 
who 
discontinued
Unadjusted HR 
(95% CI)
Weekend     p<0.001
Weekday - - 45110 71.7 6637 14.7 baseline - - -
Weekend - - 17783 28.3 2850 16.0 1.13 (1.07-1.19) - - -
Month    p<0.001  
1 - - 11687 18.6 789 6.8 baseline - - -
2  - - 11298 18.0 1383 12.2 2.92 (2.60-3.28) - - -
3  - - 10800 17.2 1857 17.2 5.35 (4.66-6.13) - - -
4  - - 10314 16.4 1843 17.9 5.78 (4.91-6.81) - - -
5  - - 9770 15.5 1839 18.8 6.31 (5.21-7.65) - - -
6  - - 9024 14.3 1776 19.7 6.26 (5.01-7.83) - - -
National holidays    p<0.001  
No  - - 58018 92.2 8487 14.6 baseline - - -
Yes  - - 4875 7.8 1000 20.5 1.62 (1.49-1.75) - - -
Phase    p<0.001  
Initiation  - - 22985 36.5 2172 9.4 baseline - - -
Continuation  - - 39908 63.5 7315 18.3 3.09 (2.70-3.54) - - -
Initiation phase adherence*     p=0.003
≥90% - - - - - - - 47419 137 baseline
80-90% - -  - - - - - 7373 22 1.05 (0.67-1.64)
<80% - -  - - - - - 6819 36 1.98 (1.37-2.86)
Month 1 adherence**     p=0.003
≥90%  - -  - - - - - 51106 171 baseline
80-90%  - -  - - - - - 7471 34 1.39 (0.96-2.00)
 <80%  - -  - -  - - - 3757 25 2.10 (1.38-3.19)
Leftmost data columns: baseline characteristics of the 780 individuals from the control arm of the original trial. Middle data columns: unadjusted mixed-effects 
logistic regression for the 780 individuals included in the analysis of suboptimal dosing implementation. Each model adjusted for clustering by patient. Age and 
distance to TB clinic modelled as linear variables. Random effect modelled on the initiation-continuation phase and month variables within the relevant 
unadjusted model. Rightmost data columns: unadjusted Cox regression for the 780 individuals included in the analysis of discontinuation. *740 individuals in 
the initiation phase adherence model and **775 in the month 1 adherence model; these exposure variables document non-adherence due to suboptimal 
dosing implementation only. Age and distance to TB clinic modelled as linear variables. All columns: no data were missing for any of the variables. - - not 
applicable, CI- confidence interval, Col- column, HR- hazard ratio, km- kilometres, OR-odds ratio, RMB- Renminbi, TB- tuberculosis
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Table 2. Adjusted odds ratios for the association between suboptimal dosing implementation and a) 
treatment month, stratified by national holidays or b) national holidays, stratified by treatment month
  National holidays
  No Yes
Treatment month, stratified by national holidays
1 baseline baseline
2 2.87 (2.55-3.23) 3.32 (2.15-5.15)
3 5.23 (4.55-6.01) 5.82 (3.81-8.90)
4 5.58 (4.72-6.58) 7.34 (4.76-11.31)
5 6.23 (5.13-7.57) 6.45 (4.11-10.12)
Treatment month
6 5.90 (4.71-7.40) 10.01 (6.27-15.98)
National holidays, stratified by treatment month
1 baseline 1.25 (0.85-1.84)
2 baseline 1.45 (1.15-1.82)
3 baseline 1.39 (1.16-1.67)
4 baseline 1.64 (1.36-1.98)
5 baseline 1.29 (1.06-1.58)
Treatment month
6 baseline 2.12 (1.71-2.62)
Adjusted regression of the association between non-adherence due to suboptimal dosing implementation and 
treatment month, stratified by national holidays (top rows) or national holidays, stratified by treatment month 
(bottom rows); Model 2. 62,893 doses from 780 individuals from the control arm of the original trial included. The 
stratum-specific ORs are adjusted for weekends, age, sex and rural-urban. Random effect modelled on the month 
variable. Age modelled as a linear variable. Results per cell presented as OR (95% CI). CI- confidence interval, OR- 
odds ratio
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Table 3. Adjusted Cox regression models of the association between early suboptimal dosing 
implementation and discontinuation
Temporal factor Hazard ratio (95% CI)
MODEL 3  
Initiation phase adherence  p=0.004
≥90% baseline
80-<90% 1.04 (0.66-1.63)
 <80% 1.97 (1.36-2.85)
MODEL 4  
Month 1 adherence p=0.004
≥90% baseline
80-<90% 1.37 (0.95-1.99)
<80% 2.06 (1.35-3.15)
Model 3 examines the association between non-adherence in the initiation phase due to suboptimal dosing 
implementation and discontinuation, adjusting for age, sex and rural-urban. It excludes individuals who 
discontinued in the initiation phase, leaving 740. Model 4 examines the association between non-adherence in the 
month 1 due to suboptimal dosing implementation and discontinuation, adjusting for age, sex and rural-urban. It 
excludes individuals who discontinued during month 1, leaving 775. Age modelled as a linear variable. CI- 
confidence interval
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 Figure 1. Lasagna plot of adherence 
Each patient of the 780 participants in the control arm of the original trial is a row in the graph; white 
indicates a dose that has not been taken. Adherence calculated as a percentage of the 90 doses taken over 
the 180-day period and then grouped into 20% adherence intervals. Rows are colored by adherence group. 
Numbers in brackets indicate the number of individuals within each 20% adherence interval. 
190x254mm (300 x 300 DPI) 
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 Figure 2. Relative contribution of discontinuation and suboptimal dosing implementation to non-adherence 
over time 
Non-adherence due to discontinuation (ceasing treatment and not re-commencing; dark grey) versus 
suboptimal dosing implementation (sporadic missed doses; light grey) over time in a) the 780 control arm 
patients from the original trial, b) the 659 patients would displayed ≥80% adherence during the initiation 
phase, c) the 121 patients who displayed <80% adherence in the initiation phase. Discontinuation is ceasing 
treatment at any stage, including only for the 90th dose. If, after the 90th dose, another was taken before 
the end of the trial, the patient is not recorded as having discontinued. Discontinuation is not the same as 
programmatically defined loss to follow-up/default. Graph style adapted from the work of Blaschke et al.[28] 
190x254mm (300 x 300 DPI) 
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 Figure 3. Gaps in adherence 
Gaps during the 90-dose medication period among the 748 participants who displayed suboptimal dosing 
implementation. Number of gaps per participant of any length plotted against a) the median gap length per 
participant, b) the maximum gap length per participant. 
190x254mm (300 x 300 DPI) 
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1ONLINE SUPPLEMENT
Temporal factors and missed doses of tuberculosis treatment: a causal associations 
approach to analyses of digital adherence data
Helen R. Stagg, James J. Lewis, Xiaoqiu Liu, Shitong Huan, Shiwen Jiang, Daniel P. Chin, 
Katherine L. Fielding
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2Additional Methods
Parent study and study population for analysis: additional details
Between 1st June 2011 and 7th March 2012, in the Heilongjiang, Jiangsu, Hunan, and 
Chongqing provinces of the People’s Republic of China, 4,173 eligible pulmonary TB 
patients placed on the standard six-month anti-tuberculosis regimen were consented to be 
enrolled in a pragmatic cluster randomized trial of electronic reminders (short message 
service [SMS] and audio reminders from a medication monitor box) to improve treatment 
adherence.(1) The thirty-six clusters were rural counties or urban districts within these 
provinces. In all arms of the study, each month a patient’s medication was placed in their 
medication monitor box by local health service staff. The box captured every date and time 
on which it was opened. These data were downloaded at the monthly clinic visits, at which 
new medication was dispensed.
Within the control arm of the trial, participants were managed according to the standard of 
care of the National TB Control Program (NTP). They received no electronic reminders to 
take their medications; their treatment was either self-administered, or supervised by family 
members or health care workers. Further restrictions to be included within the cohort 
analyzed in this study were: having no power outage problems with the medication monitor 
(resulting in box opening not being recorded), no hospital inpatient stay greater than three 
days, no pausing/stoppage of treatment due to side effects, and being enrolled into the trial 
on the same day as TB registration such that treatment had not already started and thus all 
doses could be captured.    
Measuring and defining adherence to treatment: interpreting data from the medication 
monitor
Data from the medication monitor box were interpreted as follows. If the box was opened at 
least once within each two-day dosing window this was recorded as adherence, together 
with the date. If the box was not opened within this period no adherence data were recorded 
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3by the monitor. To document non-adherence at any point, we inferred the dates of missed 
doses and thus non-adherence when the monitor did not record being opened. Data from 
the first 180 days were used in the analysis; data on doses taken after this period were not 
used.
Temporal exposures and confounding: additional information about categorization
The following temporal measures were calculated from the medication monitor data: 1) the 
day of the week on which each expected dose of medication fell, 2) the treatment month of 
the dose (expected doses 1-15 fell in month 1, etc.), 3) whether the expected dose fell on a 
Chinese national holiday, and finally 4) the first 30 expected doses were assigned to the 
initiation phase of treatment and the last 60 doses to the continuation phase. The latter 
division is the norm for TB treatment; in the initiation phase four drugs are used for two 
months, in the continuation phase two drugs are used for four months. The Chinese national 
holidays considered were New Year (January), Chinese New Year (January), Tomb 
Sweeping Day (April), Labor Day (April/May), The Dragon Boat festival (June), mid-autumn 
festival (September), and National Day (October). 
Levels of suboptimal dosing implementation in the initiation phase and month 1 were also 
calculated and categorized.
Associations between temporal factors and suboptimal dosing implementation: 
detailed methodology used
Adherence data were included for each patient up until the last dose taken before a 
permanent stoppage of treatment (discontinuation) or the 180-day end point of the regimen, 
whichever was sooner. Doses after the 180-day (90 dose) point were considered when 
assessing discontinuation, however (see Methods: Measuring and defining adherence to 
treatment).
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4Our analyses focused on the temporal factors of weekends, national holidays and, 
separately, either the initiation-continuation phase transition (Model 1) or treatment months 
(Model 2). Having drawn a directed acyclical graph (DAG), the following were deemed a 
priori confounders: age, sex and rural-urban. Assessing the effect of treatment months in 
place of the initiation-continuation phase transition was decided upon ad hoc, after 
examining our line graphs.
When building our main adjusted model (Model 1) the following factors were additionally 
considered from the DAG. On the basis of biological plausibility age, treatment month and 
distance to tuberculosis (TB) clinic were selected a priori for an assessment of goodness of 
fit as linear or categorical variables. Effect estimates across strata were compared and 
likelihood ratio tests (LRTs) undertaken. Additionally, interactions between national 
holidays/weekends and the initiation-continuation phase transition or treatment month were 
tested for using LRTs. The impact of adding a random effect for treatment month and 
initiation-continuation phase, such that their effect varied between individuals, was also 
assessed using LRTs.
Model 1 was adapted by adjusting for different sets of potential confounders in place of rural-
urban in addition to the a priori confounders. These potential confounders could not all be 
simultaneously assessed due to collinearity. The confounder sets were: distance from home 
to local TB clinic (Model 1A), medical insurance (Model 1B), occupation (Model 1C), rural-
urban and education level (Model 1D), rural-urban and total household income in the last 
year (Model 1E).
A sensitivity analysis was conducted to examine the impact of potential clustering by 
county/district, by including this variable as a fixed effect in place of rural-urban (Model 1F). 
It could not be included as a random effect, due to the small number of counties/districts.
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5Associations between early suboptimal dosing implementation and time to 
discontinuation: detailed methodology used
Non-adherence due to suboptimal dosing implementation was categorized into three levels: 
<80%, 80-89% and ≥90%. The same a priori confounders and rural-urban variable were 
adjusted for as previously, on the basis of a DAG. The validity of the proportional hazards 
assumption was assessed using a likelihood ratio test (LRT) for an interaction between time 
and the main exposure of interest.
A sensitivity analysis was also conducted for Models 3 and 4 using a fixed effect for 
county/district in place of rural-urban status (Models 3F and 4F). An additional analysis 
excluded individuals who discontinued during the last three doses (approximately a week), in 
order to focus on earlier time points of discontinuation (Models 3G and 4G).
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6Table E1. Comparison of baseline characteristics between individuals included in and 
excluded from the analysis cohort
p-values from Χ2 tests.
Analysis dataset
Exposure variables Included Col. % Excluded Col. % p-value
Overall  780 70.7 324 29.3
Sex    p=0.09
Male 535 68.6 239 73.8
Female 245 31.4 85 26.2  
Age categorised (years)   p=0.73
<30 230 29.5 103 31.8
30-39 128 16.4 49 15.1  
40-59 303 38.8 129 39.8  
60+ 119 15.3 43 13.3  
Occupation   p=0.28
Students 32 4.1 22 6.8
Worker 74 9.5 27 8.3  
Migrant Worker 74 9.5 24 7.4  
Farmer 384 49.2 156 48.1  
Unemployed/Houseworker 63 8.1 22 6.8  
Other 153 19.6 73 22.5  
Educational level   p=0.61
Illiterate 60 7.7 21 6.5
Lower middle school 494 63.3 199 61.4  
Upper middle school 130 16.7 64 19.8  
University or more 96 12.3 40 12.3  
Total household income in last calendar year 
(RMB)   p=0.92
≥20,000 320 41.0 134 41.4
<20,000 460 59.0 190 58.6  
Medical insurance   p=0.56
Rural co-op 500 64.1 210 64.8
Urban workers 92 11.8 42 13.0  
No insurance 132 16.9 56 17.3  
Other 56 7.2 16 4.9  
Marital status   p=0.41
1st marriage 551 70.6 219 67.6
Unmarried 184 23.6 80 24.7  
Other 45 5.8 25 7.7  
County    p<0.001
Baiquan 100 12.8 25 7.7
Yilan 103 13.2 20 6.2  
Rugao 78 10.0 40 12.3  
Jianhu 80 10.3 39 12.0  
Miluo 85 10.9 33 10.2  
Yueyanglou 81 10.4 38 11.7  
Fengjie 70 9.0 60 18.5  
Shapingba 79 10.1 52 16.0  
Jiangbei 104 13.3 17 5.2  
Rural/urban   p=0.79
Rural 516 66.2 217 67.0
Urban 264 33.8 107 33.0  
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7Table E1. continued
Analysis dataset
Exposure variables Included Col. % Excluded Col. % p-value
Residence p=0.97
Living in place of household 
registration 658 84.4 273 84.3
Not living in place of household 
registration 122 15.6 51 15.7  
Distance from home to local TB clinic (km)   p=0.003
<10 188 24.1 69 21.3
10-29 309 39.6 117 36.1  
30-39 149 19.1 51 15.7  
>=40 134 17.2 87 26.9  
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8Table E2. Adjusted logistic regression of the association between temporal factors 
and suboptimal dosing implementation, adjusting for different confounder sets
Adjusted models of the association between the temporal factors weekend, national holidays, and 
treatment phase and the outcome of non-adherence due to suboptimal dosing implementation. All 
models derive from Model 1. Each adjusts for the other temporal factors listed in the relevant stratum 
of the table plus age, sex and: distance from home to local TB clinic rather than rural-urban (Model 
1A), medical insurance rather than rural-urban (Model 1B), occupation rather than rural-urban (Model 
1C), both rural-urban and education level (Model 1D), rural-urban and total household income in last 
calendar year (Model 1E), county/district rather than rural-urban (Model 1F). 62,893 doses from 780 
individuals in the control arm of the original trial included. Random effect modelled on the initiation-
continuation phase variable. Age and distance to TB included as linear variables, where relevant. CI- 
confidence interval, OR- odds ratio, TB- tuberculosis.
Temporal factor OR (95% CI)
MODEL 1A
Weekend   p<0.001
Weekday baseline
Weekend 1.14 (1.08-1.20)
National holidays  p<0.001
No baseline
Yes 1.52 (1.39-1.65)
Phase  p<0.001
Initiation baseline
 Continuation 3.07 (2.68-3.51)
MODEL 1B
Weekend   p<0.001
Weekday baseline
Weekend 1.14 (1.08-1.20)
National holidays   p<0.001
No baseline
Yes 1.52 (1.39-1.65)
Phase   p<0.001
Initiation baseline
 Continuation 3.07 (2.68-3.51)
MODEL 1C
Weekend   p<0.001
Weekday baseline
Weekend 1.14 (1.08-1.20)
National holidays   p<0.001
No baseline
Yes 1.52 (1.39-1.65)
Phase   p<0.001
Initiation baseline
 Continuation 3.08 (2.69-3.53)
MODEL 1D
Weekend   p<0.001
Weekday baseline
Weekend 1.14 (1.08-1.20)
National holidays   p<0.001
No baseline
Yes 1.52 (1.39-1.65)
Phase   p<0.001
Initiation baseline
 Continuation 3.06 (2.67-3.50)
MODEL 1E
Weekend   p<0.001
Weekday baseline
Weekend 1.14 (1.08-1.20)
National holidays   p<0.001
No baseline
Yes 1.52 (1.39-1.65)
Phase   p<0.001
Initiation baseline
 Continuation 3.07 (2.69-3.52)
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9Table E2. continued
Temporal factor OR (95% CI)
MODEL 1F
Weekend   p<0.001
Weekday baseline
Weekend 1.14 (1.08-1.20)
National holidays   p<0.001
No baseline
Yes 1.52 (1.39-1.65)
Phase   p<0.001
Initiation baseline
 Continuation 3.14 (2.74-3.60)
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Table E3. Adjusted odds ratios for the association between suboptimal dosing 
implementation and the initiation-continuation phase transition, stratified by county
  Phase
  Initiation Continuation
Baiquan baseline 5.12 (3.69-7.11)
Yilan baseline 2.64 (1.88-3.71)
Rugao baseline 2.12 (1.44-3.13)
Jianhu baseline 2.63 (1.83-3.78)
Miluo baseline 3.31 (2.28-4.78)
Yueyanglou baseline 2.48 (1.65-3.73)
Fengjie baseline 4.18 (2.71-6.44)
Shapingba baseline 4.05 (2.75-5.98)
County
Jiangbei baseline 2.44 (1.73-3.45)
Adjusted regression of the association between non-adherence due to suboptimal dosing 
implementation and the initiation-continuation phase transition (Model 1), stratified by county (Model 
1G). 62,893 doses from 780 individuals from the control arm of the original trial included. The stratum-
specific ORs are adjusted for weekends, holidays, age, sex and county. Random effect modelled on 
the initiation-continuation phase variable. Age modelled as a linear variable. Results per cell 
presented as OR (95% CI). CI- confidence interval, OR- odds ratio
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Table E4. Adjusted odds ratios for the association between suboptimal dosing 
implementation and holidays, stratified by county
  Holiday
  No Yes
Baiquan baseline 0.94 (0.75-1.18)
Yilan baseline 1.49 (1.18-1.88)
Rugao baseline 1.43 (1.08-1.89)
Jianhu baseline 1.39 (1.10-1.77)
Miluo baseline 1.77 (1.37-2.28)
Yueyanglou baseline 1.57 (1.17-2.11)
Fengjie baseline 1.41 (1.02-1.94)
Shapingba baseline 1.75 (1.35-2.27)
County
Jiangbei baseline 2.37 (1.89-2.96)
Adjusted regression of the association between non-adherence due to suboptimal dosing 
implementation and holidays (Model 1), stratified by county (Model 1H). 62,893 doses from 780 
individuals from the control arm of the original trial included. The stratum-specific ORs are adjusted 
for weekends, initiation-continuation phase transition, age, sex and county. Random effect modelled 
on the initiation-continuation phase variable. Age modelled as a linear variable. Results per cell 
presented as OR (95% CI). CI- confidence interval, OR- odds ratio
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Table E5. Adjusted Cox regression models of the association between early 
suboptimal dosing implementation and discontinuation- sensitivity analysis
Sensitivity analysis of the association between suboptimal dosing implementation in the initiation 
phase or month 1, and discontinuation. Model 3F examines the association between suboptimal 
dosing implementation in the initiation phase and discontinuation, adjusting for age, sex and 
county/district (as opposed to rural-urban in Model 3). It excludes individuals who discontinued in the 
initiation phase, leaving 740. Model 3G examines the association between suboptimal dosing 
implementation in the initiation phase and discontinuation whilst excluding individuals who 
discontinued after dose 86 (688 people in the model) and adjusts for the same confounders as Model 
3. Model 4F examines the association between suboptimal dosing implementation in month 1 and 
discontinuation, adjusting for age, sex and county/district (as opposed to rural-urban in Model 4). It 
excludes individuals who discontinued during month 1, leaving 775. Model 4G examines the 
association between suboptimal dosing implementation in month 1 and discontinuation whilst 
excluding individuals who discontinued after dose 86 (723 people in the model) and adjusts for the 
same confounders as Model 4. Age modelled as a linear variable in all models. CI- confidence 
interval.
Temporal factor Hazard ratio (95% CI)
MODEL 3F  
Initiation phase adherence  p=0.001
≥90% baseline
80-<90% 1.17 (0.74-1.84)
 <80% 2.14 (1.46-3.14)
MODEL 3G  
Initiation phase adherence  p=0.001
≥90% baseline
80-<90% 1.28 (0.78-2.09)
 <80% 2.40 (1.59-3.62)
MODEL 4F
Month 1 adherence p=0.002
≥90% baseline
80-<90% 1.53 (1.05-2.22)
 <80% 2.06 (1.33-3.16)
MODEL 4G  
Month 1 adherence p=0.001
≥90% baseline
80-<90% 1.51 (1.00-2.28)
 <80% 2.39 (1.52-3.78)
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FIGURE LEGENDS
Figure E1. Flow chart of participants
Flow chart documenting participation from the original trial to this study. Side effects could 
lead to temporary or permanent medication stoppage; in either instance, adherence data 
were no longer collected.
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 Figure E1. Flow chart of participants 
Flow chart documenting participation from the original trial to this study. Side effects could lead to 
temporary or permanent medication stoppage; in either instance, adherence data were no longer collected. 
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